Clinical Trial Update: Efficacy and Safety of AIN457 (Secukinumab) in Patients With Relapsing Multiple Sclerosis [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating secukinumab (AIN457) for relapsing multiple sclerosis was terminated; results were posted in 2015.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Sclerosis

Drugs mentioned

• Secukinumab (secukinumab)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Multiple Sclerosis | Phase 2 | Status: TERMINATED | Results posted: 2015-06-01